NCT05976568

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

A Phase II/III, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Bevacizumab and/or Chemotherapy Versus Sintilimab in Combination With Bevacizumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 668 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	QL1706	7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
DRUG	Bevacizumab	15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
DRUG	Oxaliplatin injection	85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
DRUG	Capecitabine	1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
DRUG	Sintilimab	200 mg administered as IV infusion on Day 1 of each 21-day cycle

Timeline

• Start date: 2023-09-01
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2023-08-04
• Last updated: 2023-08-04

Locations

2 sites across 1 country: China